Renexxion Ireland Innovation

Renexxion Ireland Limited is a pharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (GI) disorders with its pipeline in a pill: Naronapride.

​Naronapride is a late-development stage, pan-GI prokinetic. It is a highly selective 5HT-4 agonist and D2 antagonist, both validated targets for GI motility. Naronapride has been designed to be minimally absorbed, avoiding systemic effects and acting locally in the gut lumen.

It is estimated that at least 16% of people worldwide are affected by GI-related  disorders. Currently approved therapies do not completely address the high therapeutic need. Naronapride has the potential to address the major GI indications associated with dysmotility including gastroparesis, chronic idiopathic constipation (CIC), irritable bowel syndrome- constipation (IBS-C), gastro-esophageal reflux disease (GERD) and functional dyspepsia (FD).

Naronapride is being developed for GI dysmotility in Cystic Fibrosis, a respiratory disease with significant GI morbidity. There are no other prokinetics in active development for GI dysmotility in CF, making Naronapride a potential best-in-class.